comprehensive -WSS

comprehensive

author：comprehensive 2025-10-01 00:05:26 - browse：9785

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Emergency medicine has repudiated 'excited delirium.' Now what?

WSS

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

Telehealth options flood the market as retailers push virtual care

FDA has safety concerns on CRISPR

Many immigrants are left out of maternal health programs

entertainment

comprehensive

focus

Novavax promises a turnaround & Lilly roils the obesity market

Traditional Chinese medicine benefits explored in new JAMA study

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

House GOP plan to stem drug shortages differs from Democrats’

Alkermes shareholders re

Meta's Zuckerberg and Chan on track to put $50 billion into science

How to save PrEP access — and even expand it

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

Wildfire smoke exposes gaps in outdoor worker protections

Eli Lilly to pay $200M for Beam’s stake in gene

knowledge

WHO may add ‘noma' to its list of neglected tropical diseases

FDA has safety concerns on CRISPR

Physician subsidies by hospitals soar in wake of No Surprises Act

Doctors in states that ban abortion can still help patients

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Chimpanzees, like humans and whales, get menopause: Study

focus

hotspot

Wikipedia

focus